Bruce Feinberg, DO: Let’s go down the therapeutics that are available. There are trastuzumab-dkst and trastuzumab-anns, so you’re converting those using those biosimilars?
Michael Diaz, MD: Yes.
Bruce Feinberg, DO: You are taking active patients who are on them and making the conversion?
Michael Diaz, MD: Correct—after we talk about it with the patient. We want their approval. We want their buy-in, and we want to make sure they feel comfortable. We want to make sure they understand they’re not getting an inferior product, and we also want them to be aware so that they can help us. They can help us and notify us if they notice any differences or changes.
Once again, these are biosimilars are highly similar, but we can still see unique differences in patient to patient. It is very rare, but it can happen. When I say unique differences, sometimes a patient may have an adverse effect with 1 that they did not have with the other, and that’s why we want to make sure the patient is aware. We want to get their buy-in. We want them to be aware to look out for adverse effects, and we want them to notify us if they’re having any issues or problems that are unique.
Bruce Feinberg, DO: And bevacizumab-awwb?
Michael Diaz, MD: Yes, we are using that where clinically indicated. It has most of the indications that the reference product does, so yes, we are trying to use it where we can.
Bruce Feinberg, DO: Bhavesh, go ahead.
Bhavesh Shah, RPh, BCOP: One of the reasons why we would see this hindrance in adoption rates with some of the biosimilars in oncology is that they do not carry all the indications that the reference product has. A lot of the time, providers do not know that it is because it is an orphan indication and not because there is a difference in mechanism for ovarian cancer versus lung cancer that the FDA didn’t grant this biosimilar an indication in that setting. If you go into the NCCN [National Comprehensive Cancer Network] Guidelines, they actually recommend indications besides those that are already approved on the label. That is important to understand because as we see more indications that the reference product may be getting, the biosimilar may not have those indications. The difference is because it’s an IP [intellectual property]—related issue and not because of efficacy or mechanism of action of the drug.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Bevacizumab Biosimilars Offer Promise for CRC Treatment, Wound Healing, and Cost Savings
February 28th 2024A review emphasizes that bevacizumab biosimilars demonstrate comparable efficacy to the reference product (Avastin) in the treatment of colorectal cancer (CRC) by tackling wound healing concerns in anorectal medicine.